Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases.
Dr Gorantla on a Real-World Study of HER2-Directed Breast Cancer Therapy
Vikram C. Gorantla, MD, notes real-world treatment patterns and outcomes with second-line T-DXd vs tucatinib-based therapy in HER2-positive breast cancer.
Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.
Vikram C. Gorantla, MD, discusses future directions for sequencing available therapies for patients with breast cancer who develop brain metastases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
5